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Chlamydia trachomatis (CT) infections are not report-
able in Germany and limited data on prevalence 
are available. CT screening has been offered free 
of charge to pregnant women since 1995 and to all 
women under 25 years since 2008. For symptomatic 
women and men, diagnostic testing is covered by 
statutory health insurance. We describe the estab-
lishment of a nationwide, laboratory-based, voluntary 
sentinel that electronically collects information on all 
performed CT tests with test results, test reason and 
patient information. The sentinel represents one third 
of all performed CT tests in Germany. In the period 
from 2008 to 2014, 3,877,588 CT tests were reported, 
93% in women. Women aged 20–24 years and men 
aged 25–29 years were the most frequently tested age 
groups. The overall proportion of positive tests (PPT) 
among women was 3.9% and among men 11.0%. The 
highest PPT among women was in the age groups 15–19 
(6.8%) and 20–24 years (5.9%), and among men in the 
age groups 20–24 (19.2%), 15–19 (15.4%) and 25–29 
years (14.8%). The PPT for CT was high among women 
and men younger than 25 years. Prevention is urgently 
needed. Monitoring of CT infection in Germany should 
be continued.
Introduction
Infections with Chlamydia trachomatis (CT) rank among 
the most frequent sexually transmitted infections (STI) 
in Europe and worldwide [1,2]. According to European 
data, the most affected age groups are women aged 
15–24 years and men aged 20–24 years [2,3].The CT 
infection may be asymptomatic and can, if not detected 
and treated, result in complications such as pelvic 
inflammatory disease, chronic abdominal pain, ectopic 
pregnancy, tubal sterility, a higher risk of adverse 
pregnancy outcomes for women and of epididymitis for 
men [3-10]. Evidence whether CT screening can prevent 
these complications is, however, controversial [3].
CT infections are not reportable in Germany, except 
for one federal state (Saxony), where we observed a 
continuous increase from 40.8 reported CT infections 
per 100,000 population in 2004 to 101.0 in 2012 [11]. 
However, only detected infections are reported. The 
true incidence in the population might be higher owing 
to the large proportion of asymptomatic infections that 
might remain undetected. In population-wide studies 
in Germany performed between 2003 and 2006, we 
observed a prevalence of up to 4.5% among women 
aged 17–19 years and 4.9% among men aged 25–29 
years [12-14]. Between 2003 and 2009, data on CT were 
collected through the STI sentinel surveillance system 
from 247 sites (mainly local municipality counselling 
centres for STI, followed by STI outpatient clinics, gen-
eral practitioners and other specialists) situated all over 
Germany but not representative of the general popula-
tion in Germany. CT was the most frequently diagnosed 
STI, with a positivity of 6.0% among performed tests 
[15-17]. Sixty-seven per cent of the diagnosed CT infec-
tions were among women, many of them working as sex 
workers who attended the free-of-charge local munici-
pality counselling clinics. The median age of infected 
women was 25 years and of men 31 years [15,16].
Health insurance in Germany is compulsory and indi-
viduals are covered either by statutory health insur-
ance (ca 90%) or private health insurance. Private 
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health insurance is available only to some segments of 
the population [18].
Patients in Germany can freely choose their medi-
cal practitioner, i.e. not based on place of residence. 
Laboratories do not have a defined catchment area, 
thus, there are laboratories serving only surrounding 
areas as well as laboratories receiving samples from 
all over Germany.
Since 1995, opportunistic CT screening for pregnant 
women with statutory insurance has been in place, and 
in 2008, yearly CT screening for sexually active women 
under the age of 25 years with statutory insurance, as 
well as a CT test before planned abortion, was intro-
duced in Germany [19]. Up until now, there have been 
no CT screening programmes for men. Health insurance 
companies can reimburse men and women for the 
costs of testing if they report specific symptoms or 
unspecific symptoms together with risk behaviour or if 
a sex partner has been tested positive for CT (diagnos-
tic testing). Otherwise, the CT test can be requested 
and paid by the patient.
CT has been classified in the highest priority group of 
pathogens in Germany [20]. However, data on the pro-
portion of positive tests (PPT) in different age groups 
and regions are limited. Furthermore, there are no 
data on the frequency of the different test indications 
for CT in women and on the coverage of the screening 
programme for women younger than 25 years. Except 
for Saxony, there is no information on the CT infection 
trend over time.
Figure 1
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To close this knowledge gap, we introduced a new lab-
oratory-based CT surveillance system, the ‘CT labora-
tory sentinel’ in Germany in 2010. The aim of the CT 
laboratory sentinel was to monitor CT testing data and 
infections in Germany and to evaluate the newly intro-
duced CT screening for women under 25 years of age, 
in order to develop public health recommendations for 
targeted prevention measures.
Before the laboratory-based CT-surveillance was set up, 
all laboratories testing for CT in Germany were mapped 
[21]. Of 1,504 contacted facilities, 725 (48%) responded 
to a questionnaire; 143 reported that they performed 
CT diagnostics and of those 143, 60 reported that they 
would be interested in reporting data [21].
In this paper, we report on how the CT laboratory senti-
nel was established and present the first results.
Methods
Establishment of the Chlamydia trachomatis 
laboratory sentinel
In September 2010, we started implementing a volun-
tary laboratory-based sentinel system in Germany for 
electronic and, where possible, automated collection 
of information that is routinely available in laboratories 
on CT tests. Mapping of the laboratories performing 
CT diagnostics [21] provided us with a list of laborato-
ries that expressed interest in participation and with 
information on the number of CT tests per quarter and 
catchment area. We recruited laboratories based on 
the number of performed CT tests and on the size of 
the catchment area. Our aim was to recruit laboratories 
performing many CT tests and to reach equally good 
geographical distribution in each federal state. After 
review of the geographical distribution and coverage 
in our sample, we decided to recruit additional labo-
ratories with catchment areas from underrepresented 
regions.
Through the CT laboratory sentinel, we collected ret-
rospective (back to 2008) and continuous data on 
the performed CT tests up to 31 December 2014. Data 
were reported on a quarterly basis. The laboratories 
indicated that not all variables could be selected from 
their data systems or the selection would be very time 
consuming. To keep the effort reasonable, we defined 
a standard common set of mandatory and optional var-
iables. Mandatory variables were sample and patient 
identification number, date of laboratory testing, 
test result, sex, and year of birth. Optional variables 
included date of sampling, the first three digits of the 
standard five-digit postal code of the patient, the first 
three digits of the postal code of the submitting medi-
cal practitioner, month of birth, reason for testing or 
billing codes (used for invoicing health insurance), 
pregnancy status, tested material, health insurance 
status (statutory or private) and method of testing.
If the three-digit postal code of the patient was not 
available, we used the three-digit postal code of the 
submitting medical practitioner. We generated infor-
mation on the test reason from the reported reason 
for testing or respective billing codes. Samples from 
female patients, who were tested because of symp-
toms or suspicion of infection, were categorised as 
‘Diagnostic testing’. Samples from female patients 
who were tested during pregnancy or before a planned 
abortion were categorised as ‘Screening in pregnancy’. 
Figure 2
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Women who were screened as part of the screening for 
under 25 years of age were categorised as ‘Screening 
for women under 25’.
On the basis of the year of birth, we calculated patient 
age at the time of testing. Laboratories reported the CT 
tests for the complete time period, or less if reporting 
for the complete time period was not possible.
Data were transmitted electronically. The data were 
sent to us either via email as extensible markup lan-
guage (.XML) files, comma-separated values (.CSV) 
or Excel spreadsheet (.XLS) files or in XML format via 
secure sockets layer (SSL)-encrypted Internet connec-
tion to a web service. After performing predefined 
automated plausibility checks, the received data were 
combined in a structured query language (SQL) data-
base. Unplausible variables were set to missing. The 
sample and patient numbers were MD5-encrypted and 
transmitted as 32-digit hash codes. Decryption of this 
code was not possible. If patients were tested more 
than once at the same laboratory, the 32-digit hash 
code enabled us to assign data from several samples 
over time to one patient. However, samples from the 
same patient tested in different laboratories could not 
be assigned to the same patient. If laboratories used 
different input data (for example, surname and date of 
birth in one quarter and name plus surname and date 
of birth in the subsequent quarter) to generate the 
32-digit hash codes, we were not able to trace those 
patient numbers over time. In order to understand if 
person-related analysis, such as testing frequency and 
time intervals between tests, is possible for this way 
of data collection, we proved the traceability of the 
patient identification numbers by laboratory over time.
There was no financial compensation for laboratories 
to participate in the study. The data collection proto-
col was confirmed by the data protection officer at the 
Robert Koch Institute, Berlin. Additional approval from 
an ethics committee was not deemed necessary, as no 
patient-identifying data were collected.
Data analysis
We analysed all CT tests available for the time period 
between 1 January 2008 and 31 December 2014. For the 
reported CT tests, we calculated counts and propor-
tions of the available and missing variables. We calcu-
lated the duration of the reporting period by laboratory 
as well as counts and proportions of the CT tests by 
laboratory.
We defined coverage as the proportion of CT tests 
from individuals with statutory insurance collected 
through the sentinel among all CT tests from individu-
als with statutory insurance. The National Association 
of Statutory Health Insurance provided us with data on 
all performed CT tests from individuals with statutory 
insurance for the years 2011 and 2012. We are not able 
to individually link patients or tests in the two data 
sources. Instead, we first calculated the proportion of 
individuals with statutory insurance among the CT tests 
with available information on health insurance status. 
Then, we extrapolated this proportion to all CT tests 
collected within the laboratory sentinel in the years 
2011 and 2012 and calculated the total number of CT 
tests from individuals with statutory insurance. Finally, 
we assessed the coverage of the laboratory sentinel by 
comparing the total number of CT tests from persons 
with statutory insurance in Germany and from persons 
with statutory insurance collected in the CT laboratory 
sentinel. We assumed that the coverage of CT tests for 
privately insured persons was similar.
The geographical distribution of the reported CT tests 
based on the postal codes was described as the num-
ber of CT tests per 100,000 population by federal state 
in Germany.
We described CT tests in the laboratory sentinel and 
the PPT by age group, sex, reason for testing (diagnos-
tic testing because of symptoms, screening in preg-
nancy or screening for women under 25 years of age) 
and tested material (for men).
Results
Participating laboratories and collected data
Of the 60 laboratories selected for recruitment, 24 
agreed to participate and have been reporting data 
to the CT laboratory sentinel. The reasons for refusing 
to participate were: data selection in the requested 
format was not possible (n = 10), too much effort was 
required (n = 12), CT samples were forwarded to a 
partner/alliance laboratory or organisational changes 
Figure 3
Proportion of positive Chlamydia trachomatis tests with 
95% confidence intervals, by sex, age group and test 
reason, Germany, 2008–14, among women (n = 3,577,935) 
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(n = 7), refusal without a specific reason (n = 4), other 
reasons (n = 3). Three of the laboratories refusing to 
participate were large laboratories with a nationwide 
catchment area. Currently, two laboratories are report-
ing data by using the web service; three send the data 
as XML, five as CSV and 14 as Excel spreadsheets via 
email.
By 24 November 2015, a total of 3,877,588 CT tests 
had been reported for the period from 1 January 2008 
to 31 December 2014. A total of 15 laboratories have 
reported data for each quarter of the entire study 
period. A further nine laboratories have reported data 
for a minimum of 1 month and a maximum of 4 years 
and 7 months (Table 1).
Information on the mandatory variables was miss-
ing in less than 1% of all reported CT tests and on 
optional variables between 13% and 80% (Table 2). 
Patient number was consistently coded and therefore 
traceable over the entire reporting time in 15 labora-
tories, consistently coded only for part of the time in 
seven laboratories, and two laboratories did not report 
patient identification numbers (Table 1).
Coverage
In total, 91.1% and 78.1% of CT tests with information on 
health insurance were attributable to, respectively, the 
women and men with statutory health insurance. We 
estimated that 34.3% of all CT tests performed among 
statutorily insured persons in Germany were reported 
to the CT laboratory sentinel. These estimates varied 
by federal state from 4.4% in Baden-Wurttemberg to 
60.9% in Thuringia (Table 3). The coverage was 34.6 for 
CT tests among women and 28.7% for CT tests among 
men (Table 3).
Regional distribution
The number of reported CT tests with information on 
the three-digit postal code for the entire period per 
100,000 of the population varied by region between 
141 and 14,901 (Figure 1). Based on information on 
the catchment areas provided from laboratories that 
did not report information on postal code, ca 50% 
of CT tests with missing postal codes would be from 
Saxony, around 40% from the western part of the coun-
try (Bremen, Lower Saxony, North Rhine-Westphalia, 
Hesse, Rhineland-Palatinate, Saarland and Baden-
Württemberg) and the rest from Berlin.
CT testing
Of the total of 3,877,588 reported CT tests for the period 
2008 to 2014, 92.8% (3,599,821) were done in women 
and 6.6% (255,634) in men. Among women with infor-
mation on age (3,595,447), the most frequently tested 
age groups were women aged 20–24 years, and among 
men (252,285) those aged 25–29 years, followed by 
those aged 20–24 years and 30–34 years. The propor-
tion of CT tests by age group among men and women 
are reported in Figure 2.
Reason for testing in women
Among CT tests in women with information on the rea-
son for testing, 41.9% were attributable to screening 
in pregnancy, 26.9% to screening of women under 25 
years of age and 28.7% to diagnostic tests (Figure 2).
Tested material in men
Among CT tests in men with information on tested 
specimen, 49.0% were unspecified swabs, 32.5% 
urine, 5.3% urethral, 3.1% rectal and 1.9% pharyngeal 
swabs. In 8.2% of tests, other materials were tested.
Proportion of positive tests
Among tests with valid test results (n = 3,827,792), 
3.9% (95% confidence interval (CI): 3.9–4.0) of tests 
among women and 11.0% (95% CI: 10.9–11.2) of tests 
among men were positive. PPT varied by federal state 
from 3.0% in Saarland to 6.8% in Mecklenburg-Western 
Pomerania among women and 9.0% in Saarland to 
17.0% in Mecklenburg-Western Pomerania among men.
The PPT among women differed by reason for test-
ing and age (Figure 3). Overall, the highest PPT 
was observed among women aged 15–19 years and 
20–24 years (Figure 3). The PPT when screening 
women under 25 years was 4.9% in 15–19 and 5.0% in 
20–24 year-olds. While screening tests in pregnancy 
and diagnostic testing revealed, respectively, a PPT 
of 10.0% and 9.0% among 15–19 year-olds and 5.7% 
and 7.9% among 20–24 year-olds, PPT among pregnant 
women decreased to 2.0% among women 25–29 years 
of age and was < 1% in those 30 years and older. The 
PPT in diagnostic tests also decreased with increasing 
age (Figure 3).
Among men, the highest PPT was observed among the 
age groups 20–24 years (19.2%), 15–19 years (15.4%) 
and 25–29 years (14.8%). The PPT among women and 
men decreased with age (Figure 3).
Among men, the PPT was higher in rectal (12.3%) and in 
unspecified swabs (13.4%) (Figure 4).
Figure 4
Proportion of positive Chlamydia trachomatis tests with 
95% confidence intervals among men, by tested material, 
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Discussion
We established a CT laboratory sentinel in Germany 
that electronically collects data that are routinely avail-
able in laboratories on performed CT tests; the CT labo-
ratory sentinel serves as a surveillance system. In the 
period from 2008 to 2014, we reached good coverage 
and collected a large number of samples representing 
one third of all performed CT tests in Germany, together 
with epidemiological information and data on testing. 
In total, 24 laboratories reported data on a voluntary 
basis; for the majority of the data, we had information 
for a complete time period (January 2008 to December 
2014). Completeness of the five mandatory variables 
was more than 99%, while completeness of the eight 
optional variables varied by laboratory and variable.
We estimate that we have collected 34% of all CT tests 
of individuals with statutory health insurance in the CT 
laboratory sentinel. This was possible because we were 
able to recruit some very large laboratories. Although 
this estimate is based on data from 2011 and 2012, we 
assume that we have reached at least the same cov-
erage in the following years 2013 and 2014. We also 
assume that the coverage of CT tests from individuals 
with private health insurance was similar. The coverage 
was slightly better for statutorily insured women than 
men. The reason for this is unclear. One possible expla-
nation may be that statutorily insured men are being 
tested at specialist HIV centres or at centres targeting 
men who have sex with men (MSM), and that these 
centres might be cooperating with local laboratories 
not included in the sentinel.
We were able to collect data from samples from all over 
Germany. Baden-Wurttemberg contributed the lowest 
number of reported CT tests per 100,000 population 
and also reached the lowest coverage compared with 
the other federal states. A substantial proportion of 
the CT tests with missing information on postal codes 
was reported from one laboratory with a catchment 
area in Baden-Wurttemberg, Hesse and Rhineland-
Palatinate. We therefore assume that the geographical 
Table 1
Number of reported Chlamydia trachomatis tests, proportion of tests in women, data reporting period, catchment area and 








Reporting period (number of CT tests) Patient traceability 
period2008 2009 2010 2011 2012 2013 2014
1 1,629,040 98.0 78,770 183,085 211,571 244,480 268,823 309,423 332,888 Partly
2 450,368 93.0 49,184 59,628 66,939 63,678 63,383 70,182 77,374 Complete
3 342,929 91.1 41,451 51,327 51,190 50,430 48,649 50,946 48,936 Complete
4 268,248 86.2 15,821 33,004 34,360 39,379 47,893 47,990 49,801 Partly
5 200,204 90.4 15,366 27,885 29,839 29,859 31,142 33,842 32,271 Complete
6 132,726 92.4 ND ND ND ND ND 282 132,444 Partly
7 126,170 96.6 2,609 19,884 19,836 20,892 21,919 21,663 19,367 Complete
8 95,022 74.0 8,964 10,618 11,548 12,336 14,261 15,805 21,490 Complete
9 92,824 80.2 12,162 12,882 11,529 11,746 11,998 15,684 16,823 Partly
10 83,715 92.3 8,338 11,924 12,025 12,973 12,282 13,236 12,937 Complete
11 64,806 94.9 ND ND ND ND ND 29,906 34,900 Patient number missing
12 64,133 96.6 7,705 8,449 8,894 8,937 9,482 10,118 10,548 Complete
13 59,098 99.9 5,834 14,592 15,013 14,583 9,076 Complete
14 51,755 90.7 6,524 7,371 7,128 7,857 7,715 7,460 7,700 Complete
15 49,839 84.1 3,219 7,594 7,452 7,533 7,162 7,926 8,953 Complete
16 45,708 94.7 ND ND ND ND 15,816 14,951 14,941 Partly
17 39,969 70.3 ND ND ND ND 64 20,017 19,888 Complete
18 29,573 90.9 ND ND ND 7,849 7,296 7,251 7,177 Partly
19 28,636 32.9 3,569 3,541 3,549 3,849 4,573 4,782 4,773 Complete
20 12,398 63.9 1,587 1,437 1,411 1,769 1,822 2,065 2,307 Complete
21 8,105 66.8 766 895 995 1,198 1,053 1,260 1,938 Complete
22 1,590 69.7 ND ND ND 422 397 391 380 Partly
23 564 97.2 ND ND ND 554 10 ND ND Patient number missing
24 168 92.3 ND ND ND ND 168 ND ND Complete
Total 3,877,588 92.8 261,869 454,116 493,279 540,324 584,984 685,180 857,836 
CT: Chlamydia trachomatis; ND: no data reported. 
a Laboratories sorted by number of reported CT tests.
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distribution of tested persons in these federal states 
or neighbouring areas is better than that estimated 
based on the postal codes. To obtain better regional 
data and better coverage of the CT tests from men, we 
are recruiting further laboratories for participation. An 
update of the laboratory mapping exercise would be 
desirable to indicate further potential laboratories cov-
ering Baden-Wurttemberg that were not reached in the 
first mapping.
In several laboratories, the number of performed CT 
test has increased over the years. Based on informa-
tion provided from laboratories, a substantial part of 
the observed increase can be attributed to merging 
or expansion of the laboratories. However, we are not 
able to quantify this. We believe that there has been a 
real increase in CT testing activity in Germany. Further 
analysis of the statutory insurance registry can clarify 
if the number of performed CT tests has risen since 
2008.
The majority of the reported CT tests were from women, 
as CT screening is offered to women under 25 years of 
age and pregnant women. Women aged 20–24 years 
were by far the most frequently tested age group, fol-
lowed by women aged 25–34 years. Men aged 20–34 
years were most frequently tested compared with other 
age groups. We also observed the highest PPT in age 
groups with the highest test frequency. PPT among 
both men and women was high among tests from 
younger people and decreased with age. In order to 
analyse the PPT variation by region further, sociode-
mographic information is necessary.
We observed the highest PPT among women and 
men aged 15–24 years, which is similar to several 
population-based studies in Europe [12-14,22-28]. 
National chlamydia testing data with information on 
denominator from England and Norway report PPT of, 
respectively, 7.8% and 11.5% among 15–24 year-old 
women and of 10.0% and 17.1% among 15–24 year-old 
men [27,28]. Opportunities for testing free of charge, 
especially for men, are scarce in Germany, comparison 
with England and Norway [27,28]. This impacts testing 
rates, the groups tested and the PPT.
The PPT was high among very young women screened 
during pregnancy (these data include also CT tests 
before abortion). This might be explained by a young 
age at first sexual intercourse, which several studies 
have linked to having more partners, more diverse 
sexual experiences, less frequent use of condoms, and 
increased risk for bacterial STI, pregnancy and abortion 
[29]. The PPT among CT tests in pregnancy decreased 
with increasing age and was less than 1% among 
women older than 30 years. Our data suggest that it 
is more rational to screen younger pregnant women, 
especially those under 25 years of age, than older ones. 
Furthermore, it is likely that with the given PPT in older 
pregnant women, some tests may be false positive 
and will lead to unnecessary treatment. With the cur-
rent data collected in the laboratory sentinel, we can-
not determine what proportion of positive CT tests can 
be explained by risk behaviour, such as new or multi-
ple sexual partners, other STI or history of sex work. 
Testing groups with higher prevalence is more effective 
in terms of detection rate. Age- and risk behaviour-
indicated screening in pregnancy in Germany instead 
of screening of all pregnant women should be further 
discussed. A cost–benefit analysis taking into account 
estimates of age-specific adverse health outcomes in 
Table 2
Number of Chlamydia trachomatis records with information on collected variables, and number and proportion of records 
with unknown, missing or implausible information, Germany, 2008–2014 (n = 3,877,588)
Variable Type of variable
Available Unknown, missing or unplausible
n n %
Sample number Mandatory 3,877,588 0 0.0
Patient number Mandatory 3,877,588 0 0.0
Test result Mandatory 3,856,972 20,616 0.5
Sex Mandatory 3,855,455 22,133 0.6
Year of birth Mandatory 3,859,684 17,904 0.5
Month of birth Optional 3,313,251 564,337 17.0
Three-digit postal codea Optional 3,220,557 657,031 20.4
Date of sampling Optional 776,349 3,101,239 80.0
Test reason Optional 3,496,011 381,577 9.8
Pregnancy status Optional 2,954,620 922,968 23.8
Tested material Optional 3,378,347 499,241 12.9
Method of testing Optional 2,126,643 1,750,945 45.2
Health insurance status Optional 1,207,750 2,669,838 68.9
a For 3,097,980 records (96.2%), patient three-digit postal codes were reported, and for 122,577 records (3.8%), postal codes of practitioners 
were reported.
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pregnancy due to chlamydia infection would facilitate 
these discussions.
PPT was higher in men than in women also when com-
paring only diagnostic CT tests. This was not unex-
pected, as we only reported on CT tests performed 
among men presenting with symptoms. The PPT in rec-
tal swabs compared with urethral samples was high. 
Therefore we believe that a substantial proportion of 
positive CT tests among men might be attributable to 
MSM. Although almost half of the samples tested were 
unspecified swabs, we believe based on the PPT that 
a substantial proportion can be attributable to rectal 
swabs. Among MSM screened for STI in Germany, a CT 
prevalence of 9.4% (95% CI: 7.1–12.0) has been previ-
ously reported [30].
The majority of countries in the European Union and 
European Economic Area have a system for reporting 
and monitoring diagnosed CT cases at the population 
level [31]. These are however limited to infections that 
have been diagnosed and reported. The CT detection 
rates are influenced by populations tested and testing 
volume [31]. The CT laboratory sentinel provides infor-
mation on both positive and negative test results which 
allows us to calculate the PPT and monitor it over time.
The limitations of this study are that the laboratories 
did not have an equal chance to be included in the sen-
tinel, as we were selecting laboratories based on the 
interest to participate, number of performed CT tests 
and catchment area. There may be other large labora-
tories that were not reached in the mapping phase [21] 
and thus not considered for the laboratory sentinel. 
Although we evaluated our data for coverage at least 
once per year and selected for recruitment additional 
laboratories with catchment areas in regions under-
represented in the sentinel, we could not obtain an 
even coverage in all regions. Few laboratories reported 
the optional variables, which could have resulted in 
a selection bias in these data. However, owing to the 
large number of reported CT tests, analyses describing 
these variables are still possible. Efforts are continu-
ing to improve completeness of the optional variables. 
We are unable to collect more detailed epidemiological 
information such as route of transmission and symp-
toms through the CT laboratory sentinel. Usually, 
laboratories in Germany have only very limited epide-
miological information and there is no legal basis to 
collect these data. Laboratories that have more infor-
mation need to treat this information confidentially.
Conclusion
The implementation of our CT laboratory sentinel has 
shown that it is feasible in Germany to collect, elec-
tronically and continuously, readily available data from 
laboratories with a reasonable effort that can for now 
be used instead of mandatory surveillance. We man-
aged to collect a large amount of data from all regions 
in Germany that represented around one third of all 
performed CT tests. In contrast to mandatory surveil-
lance, the CT laboratory sentinel collects information 
Table 3
Proportion of Chlamydia trachomatis tests from men and women with statutory health insurance (n = 2,964,346), collected 
in the Chlamydia trachomatis laboratory sentinel, by federal state, Germany, 2011–12 (n = 1,016,231)
Federal state (total populationa) 
Proportion of CT tests collected through the sentinel (%)
Women Men Unknown Total 
Baden-Wurttemberg (n = 10,786,227) 4.3 6.3 18.4 4.4
Bavaria (n = 12,595,891) 29.6 16.1 19.2 28.9
Berlin (n = 3,501,872) 57.9 53.2 177 57.3
Brandenburg (n = 2,495,635) 37.2 8.8 3.5 35.7
Bremen (n = 661,301) 12.2 1.9 0.0 11.5
Hamburg (n = 1,798,836) 15.3 2.4 0.7 13.5
Hesse (n = 6,092,126) 19.7 22.9 44.6 20.0
Lower Saxony (n = 7,913,502) 24.7 12.2 1.4 23.8
Mecklenburg-Western Pomerania (n = 1,634,734) 53.9 25.9 17.7 52.4
North Rhine-Westphalia (n = 17,841,956) 39.6 34.9 66.4 39.4
Rhineland-Palatinate (n = 3,999,117) 29.8 18.9 1170 29.5
Saarland (n = 1,013,352) 19.6 8.8 90.5 19.0
Saxony (n = 4,137,051) 27.7 35.4 49.0 28.4
Saxony-Anhalt (n = 2,313,280) 36.1 6.9 1.4 33.8
Schleswig-Holstein (n = 2,837,641) 22.6 3.3 5.5 21.1
Thuringia (n = 2,221,222) 60.1 82.6 41.5 60.9
Total 34.6 28.7 177.3 34.3 
CT: Chlamydia trachomatis. 
a Population by federal state in 2011 (Source: German Federal Statistical Office).
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on all performed CT tests which allows analysis of PPT 
over time. In addition, regularly conducted population-
based prevalence surveys, although costly, could help 
determine the true prevalence of CT infection in the 
population and evaluate prevention strategies.
A large PPT among young men and women and low 
awareness of CT in Germany [32] support the need 
for further prevention efforts. The CT laboratory sen-
tinel should continue to collect data and expand the 
base of participating laboratories in order to monitor 
and describe CT infection in Germany and guide pub-
lic health strategies. The participating laboratories 
should be continuously evaluated and the coverage 
and representation of different groups tested should 
be improved.
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